Abcam, ab232472, Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Retinoid X Receptor alpha/RXRA antibody. Carrier free. Suitable for IP, WB, ICC/IF and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7106,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, IP, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232472 is the carrier-free version of
ab125001
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Retinoid X Receptor alpha (RXRA) also referred to as NR2B1 is a nuclear receptor with a mass of approximately 55 kDa. RXRA functions as a transcription factor and plays a significant role in regulating gene expression by forming heterodimers with other nuclear receptors. RXRA is expressed in many tissues with notable levels in organs like the liver lungs and kidneys. Its ability to bind DNA sequences known as retinoic acid response elements allows RXRA to regulate diverse physiological processes.
Biological function summary
RXRA serves an important role in metabolic regulation especially in lipid metabolism and glucose homeostasis. It forms heterodimers with partners such as peroxisome proliferator-activated receptors (PPARs) enhancing its capacity to modulate various metabolic pathways. These heterodimers facilitate the transcription of genes that respond to nutritional changes. RXRA also influences immune responses and cell differentiation making it important for maintaining cellular health.
Pathways
RXRA operates within the retinoid signaling and lipid metabolism pathways. Through its interaction with PPARs particularly PPAR-γ and PPAR-α RXRA becomes an integral part of the signaling that controls fatty acid storage and glucose metabolism. These pathways influence cellular function and energy balance impacting the body's overall metabolic status.
RXRA has associations with metabolic diseases such as diabetes and cardiovascular disorders. Dysregulation of RXRA expression or function can disrupt lipid and glucose metabolism leading to insulin resistance and metabolic syndrome. The RXRA-PPAR-γ interaction is essential in these conditions with the pair influencing adipogenesis and inflammatory responses. Understanding and targeting RXRA interactions can provide therapeutic prospects for these metabolic disorders.